PDCD1 and colorectal carcinoma: In a prospective pilot study performed by L. Cabel et al., which included NSCLC, CRC and melanoma, the PFS and OS of patients with detectable ctDNA after anti-PD-1 ICI treatment were significantly shorter than those without ctDNA detected.